Nevertheless, the PD-1/PD-L1 blockade is limited by a lack of biomarkers, immune-related toxicity and drug resistance. So far, PD-L1 expression on tumor cells is used as predictor for successful outcome of immunotherapy. The gene discussed is PDCD1; the disease is neoplasm.